ArticleJournal of inflammation research2026
Correlation of Omentin-1 with Disease Extent and Therapeutic Response to Infliximab in Ulcerative Colitis.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ulcerative colitis (UC) is classified by both activity and extent. Accumulating evidence suggests that disease extent is an independent factor in determining poor prognosis. However, there is a significant lack of blood biomarkers that mirror lesion reach, clinicians still rely on repeated endoscopy to determine disease activity and mucosal healing. Omentin-1 is an adipokine secreted mainly by visceral adipose tissue and intestinal goblet cells that has been reported to exert anti-inflammatory and epithelial-barrier-enhancing effects. Therefore, we hypothesized that serum omentin-1 correlates with disease extent and predicts primary response to infliximab (IFX). Methods: Consecutive UC patients (n = 126) were enrolled and stratified by Montreal classification into distal (E1/E2, n = 84) or extensive (E3, n = 42) disease. Serum omentin-1 was quantified by ELISA. Clinical activity (partial Mayo) and endoscopic activity (MES) were recorded. Among 36 subjects who received standard IFX induction, response was assessed at week 14. Results: Among the 126 UC patients, serum omentin-1 levels were significantly lower in extensive than distal colitis [median: 48.60 (38.28-67.35) ng/mL vs 62.70 (58.48-73.88) ng/mL, Conclusion: Serum omentin-1 quantifies UC extent independently of activity and predicts IFX response specifically in extensive colitis, offering a blood-based tool to map disease extent and guide biologic therapy. This finding may reduce the reliance on repeated colonoscopy and support therapeutic stratification in extensive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.